Non-obstructive Coronary Artery Disease research hub

A multi-center, randomized, double-blind, placebo controlled, parallel-group Phase IIIb study evaluating the effect of inclisiran on atherosclerotic plaque progression assessed by coronary computed tomography angiography (CCTA) in participants with a diagnosis of non-obstructive coronary artery disease without previous cardiovascular events (VICTORION-PLAQUE)

This study looks at a cholesterol-lowering injection called inclisiran. Researchers want to see if adding inclisiran to standard daily statin tablets can stop or shrink fatty build-up in the heart's arteries. It is for adults with early heart disease who have never had a heart attack or stroke.